Trop2 Expression Contributes to Tumor Pathogenesis by Activating the ERK MAPK Pathway

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2010 Sep 23

PMID 20858281

Citations 119

Authors

Rafael Cubas

Sheng Zhang

Min Li

Changyi Chen

Qizhi Yao

Affiliations

Soon will be listed here.

Abstract

Background: Trop2 is a cell-surface glycoprotein overexpressed by a variety of epithelial carcinomas with reported low to restricted expression in normal tissues. Expression of Trop2 has been associated with increased tumor aggressiveness, metastasis and decreased patient survival, but the signaling mechanisms mediated by Trop2 are still unknown. Here, we studied the effects murine Trop2 (mTrop2) exerted on tumor cellular functions and some of the signaling mechanisms activated by this oncogene.

Results: mTrop2 expression significantly increased tumor cell proliferation at low serum concentration, migration, foci formation and anchorage-independent growth. These in vitro characteristics translated to increased tumor growth in both subcutaneous and orthotopic pancreatic cancer murine models and also led to increased liver metastasis. mTrop2 expression also increased the levels of phosphorylated ERK1/2 mediating cell cycle progression by increasing the levels of cyclin D1 and cyclin E as well as downregulating p27. The activation of ERK was also observed in human pancreatic ductal epithelial cells and colorectal adenocarcinoma cells overexpressing human Trop2.

Conclusions: These findings demonstrate some of the pathogenic effects mediated by mTrop2 expression on cancer cells and the importance of targeting this cell surface glycoprotein. This study also provides the first indication of a molecular signaling pathway activated by Trop2 which has important implications for cancer cell growth and survival.

Citing Articles

Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.

Chang T, Lin C, Wen S, Wu Y, Wei C, Huang J Sci Rep. 2025; 15(1):8735.

PMID: 40082588 PMC: 11906863. DOI: 10.1038/s41598-025-92697-z.

OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.

Li W, Chiang M, Weng H, Yang J, Wu H, Wu S Mol Cancer Ther. 2025; 24(2):163-175.

PMID: 39786401 PMC: 11791482. DOI: 10.1158/1535-7163.MCT-24-0588.

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.

Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis E bioRxiv. 2024; .

PMID: 39677819 PMC: 11642930. DOI: 10.1101/2024.12.02.626446.

Severe Xanthogranulomatous prostatitis mimicking prostate cancer: a case report.

Abdo Hassan W, Elmetwally A, Abdelhafeez M, Ali O J Med Case Rep. 2024; 18(1):582.

PMID: 39623396 PMC: 11613866. DOI: 10.1186/s13256-024-04870-z.

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions.

Tong Y, Fan X, Liu H, Liang T Front Immunol. 2024; 15:1495675.

PMID: 39555080 PMC: 11563829. DOI: 10.3389/fimmu.2024.1495675.

References

Meloche S, Pouyssegur J . The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007; 26(22):3227-39. DOI: 10.1038/sj.onc.1210414. View

Li N, Wang C, Wu Y, Liu X, Cao X . Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation. J Biol Chem. 2008; 284(5):3021-3027. DOI: 10.1074/jbc.M805483200. View

Bardeesy N, DePinho R . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12):897-909. DOI: 10.1038/nrc949. View

Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, HORII I . Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996; 85(5):707-20. DOI: 10.1016/s0092-8674(00)81237-4. View

Brondello J, McKenzie F, Sun H, Tonks N, Pouyssegur J . Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene. 1995; 10(10):1895-904. View

Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y . Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development. 2009; 136(11):1951-60. DOI: 10.1242/dev.031369. View

Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M . Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006; 12(10):3057-63. DOI: 10.1158/1078-0432.CCR-05-1961. View

Brandlin I, Hubner S, Eiseler T, Martinez-Moya M, Horschinek A, Hausser A . Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. J Biol Chem. 2001; 277(8):6490-6. DOI: 10.1074/jbc.M106083200. View

Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E . Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol. 2006; 16(12):1171-82. DOI: 10.1016/j.cub.2006.04.044. View

10.

Karin M . The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270(28):16483-6. DOI: 10.1074/jbc.270.28.16483. View

11.

Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S . Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis. 2003; 25(3):375-80. DOI: 10.1093/carcin/bgh019. View

12.

Zhang X, Borrow J, Zhang X, Nguyen T, Hersey P . Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene. 2003; 22(19):2869-81. DOI: 10.1038/sj.onc.1206427. View

13.

Wang J, Day R, Dong Y, Weintraub S, Michel L . Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008; 7(2):280-5. DOI: 10.1158/1535-7163.MCT-07-2003. View

14.

Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S . Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004; 112(6):1029-35. DOI: 10.1002/ijc.20517. View

15.

Muhlmann G, Spizzo G, Gostner J, Maier H, Moser P, Gastl G . TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2008; 62(2):152-8. DOI: 10.1136/jcp.2008.060590. View

16.

Grapin-Botton A . Ductal cells of the pancreas. Int J Biochem Cell Biol. 2004; 37(3):504-10. DOI: 10.1016/j.biocel.2004.07.010. View

17.

Shen Q, Uray I, Li Y, Krisko T, Strecker T, Kim H . The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2007; 27(3):366-77. DOI: 10.1038/sj.onc.1210643. View

18.

Fong D, Spizzo G, Gostner J, Gastl G, Moser P, Krammel C . TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2007; 21(2):186-91. DOI: 10.1038/modpathol.3801001. View

19.

Montagut C, Settleman J . Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009; 283(2):125-34. DOI: 10.1016/j.canlet.2009.01.022. View

20.

Kohno M, Pouyssegur J . Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog Cell Cycle Res. 2003; 5:219-24. View